Myelodysplastic syndromes(MDS) is a heterogeneous hematopoietic stem cell disorder characterized by bone marrow dysplasia and peripheral cytopenias.Therapeutic dilemmas exist in MDS because of its multifactorial pathogenetic features,heterogeneous stages and the patients generally elderly ages. This article reviews the recent progresses of drug therapy for myelodysplastic syndromes. |